Global screening of health behaviors: Introducing Lev-screening (Lev-s)-development and psychometric evaluation

PLoS One. 2024 Dec 26;19(12):e0315565. doi: 10.1371/journal.pone.0315565. eCollection 2024.

Abstract

Poor health behaviors have been identified as a critical factor for the burden on healthcare systems and individual suffering. However, comprehensive assessment of health behaviors is time-consuming and often neglected. To address this, we introduce the Lev-screening (Lev-s), a new, brief tool that covers multiple health behaviors. The Lev-s assesses ten health behaviors-physical activity, diet, alcohol use, tobacco use, illegal drug use, sleep, social relations, meaningful activities, sexual health, and screen health-using 33 items. This article details the development and psychometric evaluation of Lev-s with a sample of 2,279 participants aged 18-87. Test-retest reliability estimated as intra-class correlation coefficients for the different health behaviors ranged from .71 to .98 (n = 157), indicating moderate to excellent reliability. Lev-s showed associations with quality of life, demonstrated inter-correlations among included health behaviors, and detected group differences between individuals with and without neurodevelopmental conditions. The Lev-s exhibits satisfactory psychometric properties and holds promise as an efficient tool for screening of health behaviors.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Health Behavior*
  • Humans
  • Male
  • Mass Screening / methods
  • Middle Aged
  • Psychometrics* / methods
  • Quality of Life
  • Reproducibility of Results
  • Surveys and Questionnaires
  • Young Adult

Grants and funding

The development of the Lev-screening was funded by The Habilitation Services in Region Stockholm, Promobilia, and FoU-gruppen Medicinsk psykologi at the Karolinska Institutet. All funding was received by DS. Sponsors did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The development of the Lev-screening was funded by Promobilia A22130. All funding was received by DS. Sponsors did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.